Entertainment Trends

Significant Reductions in Bleeding with Abelacimab in Phase 2b Trial

  • 📰 Medscape
  • ⏱ Reading Time:
  • 19 sec. here
  • 7 min. at publisher
  • 📊 Quality Score:
  • News: 28%
  • Publisher: 55%

Medical News

Bleeding,Abelacimab,Phase 2B Trial

Further details from the phase 2b AZALEA trial with the factor XI inhibitor abelacimab (Anthos) show significant reductions in major and clinically relevant nonmajor bleeding compared with earlier this year because of an "overwhelming" reduction in bleeding with abelacimab in comparison rivaroxaban.

Further details from the phase 2b AZALEA trial with the factor XI inhibitor abelacimab (Anthos) show significant reductions in major and clinically relevant nonmajor bleeding compared with earlier this year because of an "overwhelming" reduction in bleeding with abelacimab in comparison rivaroxaban. Abelacimab is a monoclonal antibody given by subcutaneous injection once a month.

Details of the bleeding results have now shown that the 150-mg dose of abelacimab, which is the dose being carried forward to phase 3 trials, was associated with a 57% reduction in major or clinically relevant nonmajor bleeding, the primary endpoint of the study. In addition, major bleeding was reduced by 74%, and major gastrointestinal (GI) bleeding was reduced by 93

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in ENTERTAİNMENT

Entertainment Entertainment Latest News, Entertainment Entertainment Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

USD/JPY experiences significant drop before stabilizingUSD/JPY experienced a significant drop, losing 67 pips rapidly, before stabilizing around 151.52, slightly up by 0.03%. Japanese Producer Price Index data showed a contraction, justifying the Bank of Japan’s ultra-loose policy. Traders are now focusing on the US CPI data release on Tuesday, which is expected to show a slight moderation in inflation rates.
Source: FXStreetNews - 🏆 14. / 72 Read more »